Sera Prognostics (SERA) Competitors $6.03 -0.15 (-2.43%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SERA vs. LUCD, CODX, CSTL, AGL, INNV, SHCR, FLGT, AUNA, GRAL, and CELCShould you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), Castle Biosciences (CSTL), agilon health (AGL), InnovAge (INNV), Sharecare (SHCR), Fulgent Genetics (FLGT), Auna (AUNA), Grail (GRAL), and Celcuity (CELC). These companies are all part of the "medical" sector. Sera Prognostics vs. Lucid Diagnostics Co-Diagnostics Castle Biosciences agilon health InnovAge Sharecare Fulgent Genetics Auna Grail Celcuity Sera Prognostics (NASDAQ:SERA) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Do insiders and institutionals hold more shares of SERA or LUCD? 54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor SERA or LUCD? In the previous week, Lucid Diagnostics had 13 more articles in the media than Sera Prognostics. MarketBeat recorded 14 mentions for Lucid Diagnostics and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.91 beat Lucid Diagnostics' score of 0.21 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is SERA or LUCD more profitable? Sera Prognostics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Sera Prognostics' return on equity.Company Net Margins Return on Equity Return on Assets Sera PrognosticsN/A -51.73% -36.94% Lucid Diagnostics -1,069.87%N/A -123.54% Do analysts recommend SERA or LUCD? Lucid Diagnostics has a consensus target price of $3.69, suggesting a potential upside of 268.75%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Sera Prognostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, SERA or LUCD? Sera Prognostics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Does the MarketBeat Community believe in SERA or LUCD? Lucid Diagnostics received 25 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 67.31% of users gave Lucid Diagnostics an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformSera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Lucid DiagnosticsOutperform Votes3567.31% Underperform Votes1732.69% Which has higher valuation and earnings, SERA or LUCD? Sera Prognostics has higher earnings, but lower revenue than Lucid Diagnostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$310K656.88-$36.24M-$0.99-6.09Lucid Diagnostics$2.43M24.42-$52.67M-$1.14-0.88 SummaryLucid Diagnostics beats Sera Prognostics on 12 of the 19 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Sera Prognostics News Delivered to You Automatically Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SERA vs. The Competition Export to ExcelMetricSera PrognosticsMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.63M$3.06B$5.07B$8.90BDividend YieldN/A11.18%4.99%4.07%P/E Ratio-6.099.1287.8613.46Price / Sales656.88215.451,228.8287.66Price / CashN/A406.7839.5136.27Price / Book3.723.216.946.30Net Income-$36.24M-$32.86M$119.12M$225.93M7 Day Performance-6.37%0.56%-1.84%-1.32%1 Month Performance-17.62%-0.22%-3.65%0.60%1 Year Performance235.00%26.01%31.64%26.23% Sera Prognostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SERASera Prognostics1.0508 of 5 stars$6.03-2.4%N/A+235.0%$203.63M$310,000.00-6.09120LUCDLucid Diagnostics3.221 of 5 stars$1.00+4.6%$3.69+268.8%-23.1%$59.34M$2.43M0.0070CODXCo-Diagnostics4.3727 of 5 stars$1.08+3.8%$1.50+38.9%-27.8%$34.48M$6.81M0.00100Short Interest ↓Gap DownCSTLCastle Biosciences3.472 of 5 stars$28.45-1.5%$37.88+33.1%+41.8%$796.88M$219.79M142.26540Insider TradeAGLagilon health2.2561 of 5 stars$1.65-1.2%$6.05+266.7%-85.4%$679.83M$4.32B0.001,117Analyst ForecastINNVInnovAge1.4851 of 5 stars$4.70-1.7%$6.50+38.3%-19.0%$647.48M$763.85M0.002,350Gap UpSHCRSharecareN/A$1.43flat$1.43N/A$531.79M$445.25M-3.673,352FLGTFulgent Genetics4.1478 of 5 stars$17.28+1.6%$28.50+64.9%-37.4%$528.60M$289.21M-3.131,184Analyst UpgradeAUNAAuna3.8224 of 5 stars$7.04-2.9%$13.40+90.3%N/A$520.40M$1.04B0.0014,958Short Interest ↓News CoverageHigh Trading VolumeGRALGrailN/A$14.93-1.1%N/AN/A$501.65MN/A0.001,360Insider TradeCELCCelcuity2.3327 of 5 stars$12.78+2.5%$29.17+128.2%-2.3%$474.52MN/A0.0040 Related Companies and Tools Related Companies LUCD Competitors CODX Competitors CSTL Competitors AGL Competitors INNV Competitors SHCR Competitors FLGT Competitors AUNA Competitors GRAL Competitors CELC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SERA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SERA Stock Alerts